Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Kymera Therapeutics Inc

KYMR ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$117.39

▲ +2.60%

Market Cap $9.76B · Vol 210.33K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$9.76B

Mid Cap

Div Yield

N/A

EPS Growth

+1.72%

YoY

RSI (14)

62.10

Momentum

Beta

1.96

vs Market

52W High

$129.80

9.56% below

52W Low

$39.85

194.58% above

Volume

210.33K

Avg 218.41K

P/B

4.01

Price-to-book

ROE

-25.78%

Return on equity

Free Float

97.66%

Public shares

Shariah Compliance8 STANDARDS

✗ Kymera Therapeutics Inc (KYMR) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does KYMR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+9.18%

+4.74%

+38.92%

+42.57%

YTD

+50.87%

+182.53%

+498.62%

+117.63%

Financials & Valuation

TTM · Annual

Total Revenue	$39.21M
Net Income	$-311,351,000.00
Revenue Growth (YoY)	+466.40%
Gross Margin	100.00%
Operating Margin	-881.24%
Net Profit Margin	-794.04%
ROE	-25.78%
ROA · ROIC	-22.89% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	167.66
P/B	4.01
P/FCF	N/A
EPS Growth	+1.72%
Outstanding Shares	83.15M

Technical Indicators

50-Day SMA	$104.06
200-Day SMA	$84.64
RSI (14)	62.10
Beta	1.96
52-Week High	$129.80
52-Week Low	$39.85

Volume Today	210.33K
Avg Daily Volume (30D)	218.41K
Relative Volume	0.96x
Volatility (10D)	30.01
Volatility (30D)	43.77
Free Float	97.66%

Analyst Consensus

BUY

Current Price $117.39

Mean Target $131.38

52W Low$39.85 52W High$129.80

Current

Target

$39.85 $129.80

Current Analyst target

+11.92% upside potential · 23 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00SDHC8F9

ISINUS5015751044

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.